How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ezetimibe-rosuvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ezetimibe/Rosuvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ezetimibe/Rosuvastatin (Ezetimibe/Rosuvastatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination). Area: Cardiovascular.

marketed Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination) NPC1L1 transporter (ezetimibe); HMG-CoA reductase (rosuvastatin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ezetimibe/Rosuvastatin (Ezetimibe/Rosuvastatin) — Addpharma Inc.. This combination reduces cholesterol by blocking intestinal cholesterol absorption (ezetimibe) and inhibiting HMG-CoA reductase to decrease hepatic cholesterol synthesis (rosuvastatin).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ezetimibe/Rosuvastatin TARGET	Ezetimibe/Rosuvastatin	Addpharma Inc.	marketed	Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (rosuvastatin)
Ezetimibe + Atorvastatin	Ezetimibe + Atorvastatin	Organon and Co	marketed	Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination)	NPC1L1 (ezetimibe); HMG-CoA reductase (atorvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination) class)

Addpharma Inc. · 1 drug in this class
Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ezetimibe/Rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/ezetimibe-rosuvastatin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing